Atherogenics (AGIX) Inactive 10-Q2008 Q1 Quarterly report

Filed: 9 May 08, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	8th grade Avg

New words: automatically, Bankruptcy, bid, choose, communicated, comprehensive, confidentiality, correlation, corroborated, ensure, expiration, extinguished, extinguishment, FASB, forecasting, framework, GAAP, gain, hand, hemoglobin, hierarchy, identical, improve, indemnification, industry, ingredient, instrument, intermediate, ISP, judgment, leave, liquidity, LLC, mandated, method, pay, point, quoted, relief, renewal, repaid, repayment, retirement, retiring, statistically, strategy, supplied, supply, Title, topline, violation, worldwide

Removed: abnormal, accessed, administered, advanced, adverse, Africa, authorized, Canada, collaborative, colonnese, combination, commercializing, concomitant, conducted, consistent, continue, delayed, developed, developing, discontinuation, discover, duly, event, exclusive, Exhibit, frequently, function, heading, healthy, historically, II, intend, investigating, invoiced, Kingdom, leasehold, limited, liver, men, merit, negotiate, observed, onset, partner, platform, portion, preclude, Prograf, proprietary, protectant, pursue, regimen, represent, satisfactory, small, South, Spending, subgroup, technology, termination, thereunto, tolerability, transition, transitioning, unbilled, undersigned, United, vascular, women

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

AGIX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AtheroGenics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Russell M. Medford, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	/s/RUSSELL M. MEDFORD
	Russell M. Medford
	President and Chief Executive Officer
	Date: May 9, 2008

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AtheroGenics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark P. Colonnese, Executive Vice President, Commercial Operations and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	/s/MARK P. COLONNESE
	Mark P. Colonnese
	Executive Vice President, Commercial Operations
	and Chief Financial Officer
	Date: May 9, 2008

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.